Abstract
Introduction
In recent years, understanding of the molecular mechanisms underlying tumour cell biology has provided a variety of potential targets for drug development. One important current goal is to determine the best targets for therapeutic intervention given a particular molecular aetiology. For some targets it will be possible to develop highly specific and effective treatments, though it is likely that many pathways will prove refractory to targeting in the clinical setting. In particular, many leads with promising preclinical activity may ultimately prove effective only in specific patient subsets [1] . Therefore, agents with broad spectrum activity will presumably form the backbone of cancer therapy for some time to come. [2] . Most [3] .
Immortality is a near-universal phenotype of cancer cells that has attracted considerable interest recently in respect of therapeutic interventions
Mammalian telomeric DNA comprises extended repeats of the sequence TTAGGG ending in a 3Ј G-rich single stranded overhang on both termini. The natural end must be protected from recognition as damaged DNA to prevent cell cycle arrest in proliferating cells. In normal somatic cells the end replication problem, oxidative stress and processing by nucleases cause progressive telomere shortening during each round of cell division. Ultimately, compromised protection causes DNA damage signalling at critically shortened telomeres and telomere dependent senescence [3] . In contrast, most cancer cells aberrantly express telomerase to counteract telomere attrition, maintaining telomeres at a stable length [4] .
Telomerase is present in the vast majority of human tumours and directly controls immortality, whereas its core RNA (hTR) and protein (hTERT) subunits are transcriptionally repressed in normal cells [2] . Thus, it is widely regarded as a highly attractive cancer target and has been the subject of intense drug development [8, 9] . The main attempt so far to directly target telomeres in cancer cells is through the use of agents that bind and stabilize G4 DNA (GTAs). Because G4 DNA must be resolved to allow telomerase access, GTAs were originally envisaged as inhibitors of telomerase primer extension, though they are now also known to cause more rapid toxic effects. Many chemically diverse GTAs have been described [7] . Our focus is on the development paths of three agents that have come close to clinical testing.
A diamidoanthraquinone was the first reported GTA, showing slight preference for binding G4 over duplex DNA [10] . Intensive structure-activity optimization led to development of the trisubstituted acridine BRACO19 [11] . BRACO19 inhibits telomerase activity in cancer cells at sub-toxic concentrations and can reduce telomere length, though rapid telomere length independent growth suppression with increased telomere fusions has also been observed [12] [13] [14] [16] . Sub-toxic doses of RHPS4 inhibit telomerase in several cell lines but can also lead to rapid growth suppression and G1 arrest in the absence of significant telomere shortening [17] . However, analysis of the sensitivities of 36 tumour cell lines established that short telomere length does correlate with RHPS4 sensitivity [18] .
The compound exhibits broad spectrum activity against a range of tumour cell lines in vitro and in xenograft models of melanoma and uterine, prostate, colorectal, breast and lung cancer [17] [18] [19] [20] . Furthermore, it efficiently potentiates the activity of several other chemotherapy agents. However, context dependent effects have been observed: combination with paclitaxel was synergistic in MCF7 breast cancer cells but antagonistic in M14 melanoma cells [18, 19] [21] . Additionally, a new and more flexible synthetic route has been described for RHPS4 and substituted derivatives [22] .
. In 2006, Pharminox agreed in-licensing of rights to preclinical development of RHPS4 (http://www. pharminox.com). Two related acridinium salts were recently identified as potential backup leads on the basis of improved quadruplex binding specificity and low non-specific toxicity
Telomestatin, a natural macrocyclic pentaoxazole isolated from Streptomyces anulatus, is among the most efficient G4 stabilizing agents discovered [23] . Telomestatin inhibits telomerase activity and causes telomere shortening and apoptosis in a range of cancer cell lines in vitro and inhibits growth of leukaemia xenografts [24, 25] . Treatment also augmented apoptosis induced by daunorubicin, mitoxantrone and vincristine in human leukaemia cell lines and enhanced inhibition of colony formation by imatinib in primary chronic myeloid leukaemia (CML) cells [26] . In vivo evidence of telomestatin efficacy is currently limited, though suppression of human leukaemia cell xenografts has been shown [25] .
The [27, 28] . However, considerable interest surrounds chemistry of macrocyclic oxazoles in general. Synthetic routes for related compounds including telomestatin derivatives have been reported and these compounds are also under investigation as GTAs [29] .
Though most GTAs do appear to inhibit telomerase activity, their effects are likely to be overestimated by the telomere repeat amplification protocol (TRAP) assay [7] . An [6, 8] ).
Interestingly GTAs also elicit a growth suppressive effect on cells utilizing the alternative recombination based mechanism of telomere maintenance, alternative lengthening of telomeres (ALT) [6] . ALT is active in around 10-15% of human tumours and prevalent in certain tumour types with poor outcome including those of mesenchymal origin [30] [3] .
TRF1/2 share similar domain organization, though the N-terminus of TRF1 has an acidic region, whereas that of TRF2 is rich in Gly/Arg residues (basic region). The TRF2 N-terminus displays sequence non-specific DNA binding activity targeting to replication forks and Holliday junctions which may affect telomere replication and end protection [3, 37]. TRF1/2 perform a range of DNA remodelling activities: TRF1 bends DNA and promotes DNA looping and strand pairing by binding to non-adjacent half sites with conformational flexibility [3]. TRF2 binding to the junction of the G-overhang promotes formation of t-loops, which provide 3Ј end protection by sequestration of the G-overhang within the telomere duplex.
Recent observations point to a mechanism involving DNA melting mediated by super-coiling [3, 38] .
Shelterin proteins diversely affect telomere length, with TRF1, TIN2 and RAP1 implicated in negative length regulation. One aspect of TIN2 activity appears to be suppression of TRF1 PARsylation by tankyrase, a telomere-associated PARP which targets TRF1 to the proteasome pathway [39] . TRF2 was also characterized as a negative regulator in overexpression experiments; however, TRF2 inhibition, like POT1, results in rapid telomere deprotection [3, 6, 40] . [41] . However, TPP1 directly interacts with telomerase, recruiting it to the telomere [42] and the POT1/TPP1 complex stimulates telomerase processivity [36, 43] . [3, 6] .
POT1 appears to have a dual role in length regulation: protection of the single stranded region may prevent telomerase access and in this context POT1 has been implicated as the effector of TRF1 dependent negative length regulation

In addition to length regulation, shelterin proteins play essential roles in suppression of DNA damage signalling and inappropriate repair by homologous recombination and non-homologous end-joining. Disruption of these protective functions (telomere 'uncapping') occurs in ageing normal
The roles of other shelterin proteins in cooperating with TRF2 and POT1 to suppress damage signalling and repair remain to be fully investigated, though targeting TPP1 or TIN2 can also be cytotoxic at least in some cells [45, 46] . Interestingly, recent observations point to the existence of specific shelterin subcomplexes with distinct roles in modulating telomere protection in vivo [46] . In particular, selective targeting of TIN2 subcomplexes containing POT1/TPP1 or TRF2 using a TIN2 deletion mutant specifically cooperated with p53 deficiency to induce cell death, whereas senescence was induced in p53 wild-type cells [46] . These observations suggest that appropriate pharmacological agents tailored to disrupt specific shelterin components or subcomplexes might elicit a variety of damage phenotypes, potentially with selectivity for different cancer genotypes.
Shelterin targeting approaches
Due to the complexity of drug development even in its early phases, in order to have confidence that targeting the telomere will be fully validated in the clinic it is appropriate to explore a range of targets.
Therefore, it is timely to consider strategies for compound discovery with shelterin as the focus. However, the protein components of shelterin are not generally regarded as potential targets in their own right, with intervention studies frequently focused on functional rather than translational questions [6] .
Because shelterin components may prove difficult to drug, particularly in the case of potentially targeting protein-protein interactions, novel discovery solutions may need to be applied to identify promising leads. Encouragingly, there is a growing list of small molecule inhibitors of similar unconventional targets. Development of the Bcl2 homology domain 3 (BH3)-mimetic Bcl2
inhibitor ABT-737 using 'structure/activity relationship (SAR) by nuclear magnetic resonance (NMR)' provides notable proof-of-concept that fragment based screening coupled with structure led design is an appropriate approach [47] .
As an example of the application of this general strategy to shelterin, we submitted the structure of the TRF1/TIN2-peptide interaction ( [35] [48] .
Nine probe clusters were found with the top ranking cluster localized in a cleft adjacent to the TIN2 peptide binding site (Fig. 1A) . Mutation either of TRF1-F142 or of TIN2-L260 is sufficient to ablate TRF1/TIN2 interaction in 293T cells [35] . The predicted site is in close juxtaposition with F142 and at the lip of the hydrophobic pocket which interacts with L260. The same analysis performed for the TRF2/TIN2 structure 3BU8 [35] [49] . Given the considerable structural understanding of several shelterin components [3] , structure based design using similar algorithms seems a rational approach to identify suitable ligands.
Cell based assays could provide a second general approach to identify shelterin inhibitors [2] . Importantly, many interactions could be addressed without pre-existing knowledge of the pathway anatomy. We recently reported that promoter screening can identify inhibitors of hTERT expression [50] . Similar assays might be justified for some shelterin related targets such as TRF2, which is overexpressed in several human tumours and may play a role in drug resistance in some settings [6, 51, 52] [58] this is a tantalizing prospect from a drug development point of view.
Three validated reagents, known telomerase inhibitors BIBR1532 [59, 60] and suramin [61] and commercially available general inhibitor of ATM/ATR kinase, postulated to rescue viral cytotoxicity by blocking incorporation of mutant telomere repeats through inhibition of telomerase in the case of BIBR1532 and Suramin [60, 61] , or by blocking the downstream DNA damage signalling that ensues from telomere uncapping in the case of the ATM/ATR inhibitor [62] , increased cell viability compared to Ad-hTR-mut alone (Fig. 2B) 
